- Home
- NA vs IMMX Comparison
NA vs IMMX Comparison
Compare NA & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NA | IMMX |
|---|---|---|
| Founded | 2019 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.5M | 82.6M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NA | IMMX |
|---|---|---|
| Price | $3.02 | $6.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 197.6K | ★ 1.3M |
| Earning Date | 08-15-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,369,693.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.75 | $1.34 |
| 52 Week High | $31.48 | $7.73 |
Technical Indicators
Market Signals| Indicator | NA | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 30.36 | 65.76 |
| Support Level | $2.75 | $4.50 |
| Resistance Level | $3.16 | $7.73 |
| Average True Range (ATR) | 0.28 | 0.68 |
| MACD | -0.08 | 0.20 |
| Stochastic Oscillator | 17.07 | 63.80 |
Price Performance
Historical ComparisonAbout NA Nano Labs Ltd
Nano Labs Ltd operates as a fabless IC design company and product solution provider in China. It engages in the development of HTC chips, HPC chips, distributed computing and storage solutions, smart-NICs, vision computing chips, and distributed rendering. Its products comprise Cuckoo 1.0 Chip, Cuckoo 2.0 Chip, and Darkbird 1.0 Chip. Majority of the company revenue comes from China.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.